Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level

Launched by AIN SHAMS UNIVERSITY · Jun 29, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a way to detect early heart problems in people with psoriatic arthritis, a condition that affects the skin and joints. Specifically, the study focuses on the right side of the heart, which can sometimes start to work less well before any symptoms appear. Researchers will use a special heart ultrasound test called right ventricular strain echocardiography to find these early changes. They are also interested in how a blood protein called endostatin might be related to these heart changes.

The study is open to adults between 20 and 50 years old who have psoriatic arthritis but do not have any obvious heart symptoms. People with other serious health conditions or certain family histories won’t be able to join. If eligible, participants can expect to undergo heart ultrasound tests and blood tests to help doctors better understand how psoriatic arthritis might affect the heart early on. This research aims to find ways to spot heart problems sooner so they can be treated before becoming serious.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Psoriatic arthritis patients according to CASPAR criteria
• • Psoriatic arthritis patients without overt cardiovascular symptoms
• • Patients with age between 20 to 50 years of age
• Exclusion Criteria:
• • Other systemic autoimmune diseases
• • Patients with a history of known valvular disease, atrial fibrillation or any other arrhythmia , heart failure, ischemic cardiomyopathy severe obstructive pulmonary diseases and metabolic syndrome.
• • Patients with medical disorders as renal, congenital heart diseases, hematological disorders and cancer patients.
• • Patients taking certain drugs that have been confirmed to be risk factors for PAH such as appetite suppressant intake drugs (aminorex, fenfluramine derivatives and benfluorex) and chemotherapeutic agents.
• • Family history of myocardial infarction, cerebrovascular disease or sudden death before the age of 65y in females and 55 y in males.